flow semaglutide clinical trial Contrary to popular belief: GLP-1 weight loss medications are NOT all about aesthetic weight loss, they REDUCE risk of cardiovascular death, all cause mortality, and now, progression of kidney disease! Just published Efficacy of Oral Semaglutide: Overview

doi: 10.1038/s41580-020-00324-8 72 KaganVEMaoGQuFAngeliJPFDollSCroixCSet al

FDA proposes excluding semaglutide, tirzepatide from 503B bulks list

Challenge: High Price & Limited Reimbursement for Obesity Drugs to Limit Market Growth Though semaglutide is frequently utilized to treat type 2 diabetes, its application in the treatment of obesity (e.g., Wegovy) is complex by the higher cost of treatment & the lack of insurance coverage

Despite existing preclinical and clinical evidence indicating that HTY possesses pathway-specific mechanisms, further investigation is required to comprehensively elucidate its interactions with multiple targets, validate its efficacy in specific disease contexts, and ensure its safe and effective application in clinical environments